Frank Diamond

Managing Editor

The appropriate cliché at the appropriate moment can have an impact. For instance, hearing “the right hand doesn’t know what the left hand is doing” in a hospital might be enough to spin you right back out the revolving door. You know the horror stories. Wrong limb amputated. Forgotten utensils cozying up to innards for the long haul. Those are the sensational examples, but care coordination — or lack of it — was and remains a vexing problem. This story by Kaiser Health News describes it as health care’s “dirty little secret” but it’s something we’ve been reporting on for a long time.

Another phrase that goes way back: physician buy-in. Well, turns out that physicians may buy into care coordination in a big way. About 20 percent of physician practices now employ care coordinators, according to the 2013 Staff Salary Survey by Physicians Practice magazine, a practice management publication for doctors.

Editorial Director Bob Keaveney says that the time was right to include care coordinators in the publication’s survey. “Health care is changing,” says Keaveney. “We are theoretically doing away with the volume-based system of reimbursing providers and transforming into a value-based system that will pay for outcomes and quality of care. Outpatient medical practices typically have five or fewer physicians, and traditionally have not tried to perform complex, holistic case-management that might track patients on everything from their diet to their mental health status.

“That’s why we didn’t have it in the survey before. But in this era of accountable care, practices are realizing that outcome-based population-management is how they will increasingly be paid, and that will require coordination. So we thought it was time to ask whether practices are hiring care coordinators. Still, I was surprised to see that 20 percent have already done so.”

We’re betting that medical directors are pleasantly surprised as well. 

Frank Diamond is managing editor of Managed Care.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.